Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/1/2002 First Published: 4/1/2001


1.		Phase IV Study of Letrozole (Femara) as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer (Summary Last Modified 07/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				NOVARTIS-CFEM345A-US10 NCT00014638


2.		Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				CFEM345EBR01 NCT00237133

Last Modified: 3/21/2006 First Published: 6/1/1998


3.		Phase III Randomized Comparison Study of Letrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Women with Stage IIIB, Metastatic, or Recurrent Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-2026701025 CGS-20267, NCI-V98-1388

Last Modified: 1/7/2009 First Published: 1/1/2000


4.		Phase III Randomized Study of Adjuvant Letrozole Versus Tamoxifen in Postmenopausal Women With Operable, Hormone Receptor-Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				30 and over				Pharmaceutical / Industry				IBCSG-1-98 DAN-DBCG-IBCSG-1-98, FRE-FNCLCC-IBCSG-1-98, EU-99022, IBCSG-18-98, NOVARTIS-2026703019, NCT00004205, BIG-I-98


5.		Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				Biomed 777-CLP-29 NCT00044291

Last Modified: 8/20/2008 First Published: 3/24/2005


6.		Phase III Randomized Study of Immediate Versus Delayed Zoledronate for Prevention of Bone Loss in Postmenopausal Women With Stage I-IIIA Breast Cancer Initiating Letrozole After Prior Treatment With Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				Postmenopausal				NCI				NCCTG-N03CC NCT00107263, N03CC, NCCTG N03CC


7.		A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				50 and over				Pharmaceutical / Industry				CFEM345D2407 NCT00171704


8.		Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				No age specified				Pharmaceutical / Industry				CFEM345D2411 NCT00248170


9.		Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CFEM345DFR04 NCT00329940

Last Modified: 9/1/1994


10.		Phase II Randomized Study of Two Doses of Letrozole in Postmenopausal Women with Hormone-Refractory Metastatic Breast Cancer (Summary Last Modified 09/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				postmenopausal				NCI				NCCTG-933253 NCCTG-93-32-53

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute